These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 33287933)
1. Immunohistochemical expression of ATRX in gliomas. Jalal JA; Rowandizy AIS; Ismael AT Cell Mol Biol (Noisy-le-grand); 2020 Aug; 66(7):131-135. PubMed ID: 33287933 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of MGMT in Gliomas. Jalal JA Cell Mol Biol (Noisy-le-grand); 2020 Jul; 66(5):20-24. PubMed ID: 33040807 [TBL] [Abstract][Full Text] [Related]
3. ATRX loss in glioneuronal tumors with neuropil-like islands indicates similarity to diffuse astrocytic tumors. Kakkar A; Nambirajan A; Kaur K; Kumar A; Mallick S; Suri V; Sarkar C; Kale SS; Garg A; Sharma MC J Neurooncol; 2016 Oct; 130(1):63-68. PubMed ID: 27469217 [TBL] [Abstract][Full Text] [Related]
4. ATRX in Diffuse Gliomas With its Mosaic/Heterogeneous Expression in a Subset. Purkait S; Miller CA; Kumar A; Sharma V; Pathak P; Jha P; Sharma MC; Suri V; Suri A; Sharma BS; Fulton RS; Kale SS; Dahiya S; Sarkar C Brain Pathol; 2017 Mar; 27(2):138-145. PubMed ID: 26833422 [TBL] [Abstract][Full Text] [Related]
5. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations. Ogishima T; Tamura K; Kobayashi D; Inaji M; Hayashi S; Tamura R; Nariai T; Ishii K; Maehara T Brain Tumor Pathol; 2017 Jan; 34(1):20-27. PubMed ID: 28251430 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion. Yamamichi A; Ohka F; Aoki K; Suzuki H; Kato A; Hirano M; Motomura K; Tanahashi K; Chalise L; Maeda S; Wakabayashi T; Kato Y; Natsume A Brain Tumor Pathol; 2018 Apr; 35(2):106-113. PubMed ID: 29550880 [TBL] [Abstract][Full Text] [Related]
8. Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion. Brendle C; Hempel JM; Schittenhelm J; Skardelly M; Tabatabai G; Bender B; Ernemann U; Klose U Clin Neuroradiol; 2018 Sep; 28(3):421-428. PubMed ID: 28488024 [TBL] [Abstract][Full Text] [Related]
9. Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade. Mur P; Mollejo M; Hernández-Iglesias T; de Lope ÁR; Castresana JS; García JF; Fiaño C; Ribalta T; Rey JA; Meléndez B J Neuropathol Exp Neurol; 2015 Mar; 74(3):241-9. PubMed ID: 25668564 [TBL] [Abstract][Full Text] [Related]
10. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas. Burford C; Laxton R; Sidhu Z; Aizpurua M; King A; Bodi I; Ashkan K; Al-Sarraj S Br J Neurosurg; 2019 Oct; 33(5):536-540. PubMed ID: 31018710 [No Abstract] [Full Text] [Related]
11. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286 [TBL] [Abstract][Full Text] [Related]
12. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1 Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762 [TBL] [Abstract][Full Text] [Related]
13. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas. Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887 [TBL] [Abstract][Full Text] [Related]
14. ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma. Babikir H; Wang L; Shamardani K; Catalan F; Sudhir S; Aghi MK; Raleigh DR; Phillips JJ; Diaz AA Genome Biol; 2021 Nov; 22(1):311. PubMed ID: 34763709 [TBL] [Abstract][Full Text] [Related]
15. [Expression and significance of ABCG2 in human malignant glioma]. Chu L; Huang Q; Zhai DZ; Zhu Q; Huo HM; Dong J; Qian ZY; Wang AD; Lan Q; Gao YL Ai Zheng; 2007 Oct; 26(10):1090-4. PubMed ID: 17927879 [TBL] [Abstract][Full Text] [Related]
16. [Application of ATRX in diagnosis and prognostic evaluation of glioma]. Li Z; Piao YS; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):690-694. PubMed ID: 29050070 [No Abstract] [Full Text] [Related]
17. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation. Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234 [TBL] [Abstract][Full Text] [Related]
18. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations. Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431 [TBL] [Abstract][Full Text] [Related]
19. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111 [TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience. Alan O; Telli TA; Tuylu TB; Arikan R; Demircan NC; Ercelep O; Kaya S; Babacan NA; Atasoy BM; Bozkurt S; Bayri Y; Gul D; Ekinci G; Ziyal I; Dane F; Yumuk PF J Oncol Pharm Pract; 2021 Mar; 27(2):329-339. PubMed ID: 32349641 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]